CIVALLERO, Monica
 Distribuzione geografica
Continente #
NA - Nord America 2.597
EU - Europa 1.016
AS - Asia 409
SA - Sud America 7
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 4.036
Nazione #
US - Stati Uniti d'America 2.590
GB - Regno Unito 356
IT - Italia 218
SE - Svezia 145
CN - Cina 141
SG - Singapore 109
DE - Germania 87
HK - Hong Kong 67
UA - Ucraina 43
TR - Turchia 42
FR - Francia 36
FI - Finlandia 29
IE - Irlanda 27
BG - Bulgaria 23
BE - Belgio 18
IN - India 13
ID - Indonesia 9
CA - Canada 7
JP - Giappone 7
VN - Vietnam 7
MY - Malesia 6
LT - Lituania 5
NL - Olanda 5
RU - Federazione Russa 5
CH - Svizzera 4
CL - Cile 4
A2 - ???statistics.table.value.countryCode.A2??? 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
IR - Iran 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BR - Brasile 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 4.036
Città #
Fairfield 375
Southend 304
Chandler 259
Woodbridge 236
Ashburn 233
Santa Clara 166
Houston 155
Ann Arbor 130
Seattle 119
Cambridge 117
Nyköping 109
Wilmington 104
Singapore 87
Jacksonville 82
Dearborn 78
Hong Kong 66
Modena 53
Beijing 38
San Diego 38
New York 37
Dublin 27
Izmir 27
Princeton 25
Sofia 23
Fremont 22
Frankfurt am Main 21
Eugene 19
Brussels 18
London 18
Cologno Monzese 16
Helsinki 15
Milan 14
Norwalk 12
Des Moines 10
Jakarta 9
San Giuliano Milanese 9
Bremen 8
Falls Church 8
Brusaporto 7
Chicago 7
Parma 7
Dong Ket 6
Munich 6
Redwood City 6
Boardman 5
Latina 5
Ottawa 5
Pisa 5
Rome 5
Bologna 4
Nanjing 4
Nova Milanese 4
Shanghai 4
Arezzo 3
Ascoli Piceno 3
Atlanta 3
Chongqing 3
Grafing 3
Hefei 3
Kuala Lumpur 3
Kunming 3
Naples 3
Phoenix 3
Reggio Emilia 3
Tappahannock 3
Auburn Hills 2
Augusta 2
Barletta 2
Belgrade 2
Bereguardo 2
Brno 2
Changsha 2
Clearwater 2
Desio 2
Edinburgh 2
Fisciano 2
Genoa 2
Guangzhou 2
Indiana 2
Lappeenranta 2
Las Vegas 2
Leawood 2
Lima 2
Los Angeles 2
Mansfield 2
Melzo 2
Merate 2
Modigliana 2
Mondolfo 2
Prescot 2
Quinto di Treviso 2
Rende 2
Saint Louis 2
Sant'Ilario d'Enza 2
Washington 2
Wuhan 2
Zurich 2
Almaty 1
Almere Stad 1
Amsterdam 1
Totale 3.270
Nome #
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 280
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 245
Activity of BKM120 and BEZ235 against lymphoma cells 242
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 232
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 219
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 206
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 199
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 190
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 188
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 187
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 185
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 185
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 184
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 161
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 152
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 147
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 119
Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply 109
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project 108
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 96
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project 95
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 87
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 79
COVID-related disruption in mammographic screening: a year later. 66
The Value and relevance of T-cell lymphoma registries 62
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network 33
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 26
Totale 4.082
Categoria #
all - tutte 17.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.289


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020554 0 0 0 0 57 109 125 76 81 42 39 25
2020/2021742 72 99 46 71 87 45 40 79 31 83 51 38
2021/2022555 36 29 63 29 9 64 36 22 44 46 107 70
2022/2023648 74 114 44 66 43 95 7 57 88 7 25 28
2023/2024421 18 24 18 50 82 34 43 47 5 17 48 35
2024/2025379 50 11 36 103 179 0 0 0 0 0 0 0
Totale 4.082